Back

Mitochondrial Imaging Detects Early Cardiac Responses to Cancer Immunotherapy

Chae, H.-D.; Shrestha, U.; Das, M.; Vasanawala, M. S.; Behl, D.; Davar, D.; Srinivas, S.; Colevas, A. D.; Sunwoo, J.; Del Mar, N.; Pierini, M.; Guillen, M.; Garcia, J.; Omidvari, N.; Gupta, N.; Cabrera, H.; Blecha, J.; Cherry, S. R.; VanBrocklin, H.; Moslehi, J.; Seo, Y.; Levi, J.

2025-10-17 radiology and imaging
10.1101/2025.10.13.25337690 medRxiv
Show abstract

One Sentence Summary[18F]F-AraG PET noninvasively monitors therapy-induced cardiac effects and anti-tumor immunity to guide patient care. Advances in cancer therapy have improved survival but introduced substantial cardiac risk. Mitochondrial dysfunction underlies cardiotoxicity from conventional therapy, while T cell infiltration drives immunotherapy-related myocarditis. Early detection remains challenging, as current biomarkers and imaging lack sensitivity. Here, we show that [18F]F-AraG, a mitochondrial PET tracer that images both activated T cells and cardiomyocytes, may provide an early biomarker of cardiac involvement across different cancer therapies. Healthy cardiac uptake was clearly detectable, consistent across age and sex, and spatially uniform. In patients with cancer, conventional therapy increased cardiac uptake, while immune checkpoint inhibitors induced further increases and regional heterogeneity suggestive of T cell infiltration. Abnormal [18F]F-AraG cardiac uptake patterns were observed alongside ECG abnormalities. These findings establish [18F]F-AraG PET as a first-in-class imaging tool for simultaneous assessment of early anti-tumor immunity and cancer therapy-related cardiac effects.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.